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Abstract: Prolonged agonist exposure of many G-protein coupled receptors induces a 
rapid receptor phosphorylation and uncoupling from G-proteins. Resensitization of these 
desensitized receptors requires endocytosis and subsequent dephosphorylation. Numerous 
studies show the involvement of phospholipid-specific phosphodiesterase phospholipase D 
(PLD) in the receptor endocytosis and recycling of many G-protein coupled receptors  
e.g., opioid, formyl or dopamine receptors. The PLD hydrolyzes the headgroup of a 
phospholipid, generally phosphatidylcholine (PC), to phosphatidic acid (PA) and choline 
and is assumed to play an important function in cell regulation and receptor trafficking. 
Protein kinases and GTP binding proteins of the ADP-ribosylation and Rho families 
regulate the two mammalian PLD isoforms 1 and 2. Mammalian and yeast PLD are also 
potently stimulated by phosphatidylinositol 4,5-bisphosphate. The PA product is an 
intracellular lipid messenger. PLD and PA activities are implicated in a wide range of 
physiological processes and diseases including inflammation, diabetes, oncogenesis or 
neurodegeneration. This review discusses the characterization, structure, and regulation of 
PLD in the context of membrane located G-protein coupled receptor function. 
Keywords: phospholipase D; G-protein coupled receptor; internalization; endocytosis; 
desensitization; recycling; resensitization 
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1. Introduction 
Phospholipase D (PLD) is a widely distributed phospholipid-specific diesterase that hydrolyzes 
phosphatidylcholine (PC) to phosphatidic acid (PA) and choline. PLD is rapidly activated in response 
to extracellular stimuli, and the generation of PA is considered to mediate many biological functions 
attributed to PLD and to play an important role in the regulation of cell function and activity. This 
includes a wide array of cellular responses as calcium mobilization, secretion, superoxide production, 
endocytosis, exocytosis, vesicle trafficking, glucose transport, rearrangement of actin cytoskeleton, 
mitogenesis and apoptosis [1]. PLD superfamily members are widely distributed and found in viruses, 
bacteria, yeast, plants and animals. To date, more than 4000 PLD enzymes have been entered into the 
NCBI GenBank. The present review focuses on mammalian PLDs and their roles in the G-protein 
coupled receptor function. For the first time, the PLD activity in human tissue has been described [2]. 
Two mammalian PLD genes, PLD1 and PLD2, both with two splice variants have been identified [3–5]. 
In line with a role for PLD enzymes in different cellular tasks, PLD1 and PLD2 show a diverse 
subcellular distribution. PLD1 is found throughout the cell, but primarily localizes to intracellular 
compartments, including the Golgi apparatus, endosomes, and the perinuclear region [6–8]. PLD2 is 
almost exclusively present at the plasma membrane in lipid raft fractions [9]. Also, PLD1 is found in 
lipid rafts. The PLD activity appears to be present in nearly all cell types. PLD1 and PLD2 are both 
robustly expressed in heart, brain, and spleen. PLD1 exhibits low expression in peripheral blood 
leukocytes and synovial tissue [10], and PLD2 is poorly expressed in liver, skeletal muscle [11] and 
articular chondrocytes [12]. Both PLD enzymes have been shown to associate with membrane 
receptors including G-protein coupled receptors (GPCR), receptor tyrosine kinases or integrins, which 
all mediate signalling of PLD activation. GPCRs constitute a large group of membrane binding 
receptors known to modulate a wide range of biological responses, including cell growth, differentiation, 
migration, and inflammatory processes. Extracellular stimuli trigger dissociation of Gα and Gβγ 
heterotrimeric G proteins. Uncoupled heterotrimer subunits elicit signalling cascades through downstream 
effector proteins. Many of these pathways elicit functional responses through signalling to PLD in 
multiple ways. On the other side, the PLD influences GPCR function in many respects. PLD-generated 
PA affects the GPCR function via modulation of vesicle trafficking, endocytosis and membrane 
receptor recycling. 
2. PLD Structure and Regulation of PLD Activity 
The PLD enzyme is characterized by four conserved regions (I–IV), which form the catalytic core 
and is flanked by regulatory sequences. Domain II and IV are particularly highly conserved and 
contain the invariant charged motif designated HKD. The catalytic motif denotes the HxxxxKxD 
sequence, where the amino acids are histidine (H), any amino acid (x), lysine (K) and aspartic acid (D). 
The HKD motif responsible for catalytic activity is conserved among all superfamily members. Higher 
order PLD enzymes are composed of non-conserved regulatory domains. Duplication of the HKD 
motifs and the repetition of four short motifs, between domains I and II and between domains III  
and IV, have led to the proposal that eukaryotic PLD genes may be the result of a gene duplication event 
and that PLD may be a bilobed enzyme [13]. The importance of HKD motif was verified by mutational 
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studies. Substitution of residues in either HKD motif in the PLDs inactivated the enzyme [14]. Other 
highly conserved regions of the PLD genes are the phox consensus sequence (PX), the plekstrin 
homology (PH) domain and the PI4,5P2 binding site (for the overview about PLD structure, please see 
Figure 1). The PH domain bind anionic phospholipids such as PI3,4P2 or PI4,5P2 with low specificity 
and is important for the localization of the protein for palmitoylation at two conserved cysteine 
residues, as either careful deletion or point mutation causes mislocalization of the proteins [15]. However, 
deletion of the PH domain demonstrated that it is not required for enzymatic activity and furthermore 
did not alter the dependence on PI4,5P2 for catalysis [16,17]. This finding led to the discovery of the 
PI4,5P2 binding motif. The motif is located between the both HKD motifs and is requisite for catalytic 
activity [18]. The PX domain binds polyphosphoinositides such as phosphatidylinositol trisphosphate 
(PI3,4,5P3) with high specificity, and anionic lipids with lower specificity, but this domain has also 
been implicated in protein interactions with regulatory proteins, including dynamin and Grb2 (Growth 
factor receptor-bound protein 2) [19,20]. 
Figure 1. Domain structure of mammalian phospholipase D (PLD) isoforms. The PLD 
isoforms PLD1 (1074 amino acids) and PLD2 (933 amino acids) contain N-terminal PX 
and PH domains and the highly conserved domains I–IV. The domains II and IV contain 
HKD sequence motifs that are necessary for catalytic activity. N-terminal to domain III is a 
well conserved basic sequence that binds PI(4,5)P2. PLD1 is distinguished by a loop 
region that seems to contribute to the regulation of PLD1 activity. 
 
The two PLD isoforms, PLD1 and 2, share 50% sequence homology, mostly at the catalytic domain 
by a viable length of a conserved loop region N-terminal between the HKD and the PI4,5P2 motif. 
PLD1 harbors an extended thermolabile loop prone to proteolytic cleavage [21]. The length of this 
loop region is variable dependent on the splice variant (PLD1a = 116 aa versus PLD1b = 78 aa), while 
PLD2 does not possess a significant loop region [4]. The loop region has been proposed to function as 
a possible negative regulatory element, as deletion of this region from PLD1 increased its basal 
activity threefold [17]. Shortened splice variants of both PLD1 and PLD2 have been identified that 
compose catalytically inactive enzyme. Expression of these inactive enzymes is observed in different 
tissues, including the brain, but their function is still unknown [5]. Besides palmitoylation, PLD1, but 
not PLD2, is multimonoubiquinated at the PH domain in a catalytic and palmitoylation-dependent 
manner. It was demonstrated that the ubiquitination is important for modulation of  protein localization 
and curbing lipase activity [22]. 
Mammalian PLD enzymes catalyse a hydrolysis reaction to produce PA. The in vivo nucleophile is 
water, which attacks the diester phosphate group of PC. Both HKD motifs of PLD are needed for the 
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enzymatic action of hydrolysis [14]. Based on biophysical data, the current model of PC catalysis is a 
two-step mechanism. Initially, the amino-terminal HKD motif is proposed to be protonated on the 
histidine. Subsequently, PC enters the active pocket of PLD containing both HKD motifs. Next, free 
choline is released by liberation of the amino-terminal proton, and a PLD-PA intermediate is thought 
to be formed with the histidine of the carboxy-terminal HKD domain. Finally, the amino histidine  
re-acquires a proton from a water molecule, leaving the hydroxyl group to attack the PLD-PA 
intermediate and release PA [11,23]. Interestingly, for mammalian PLDs, short chain primary alcohols 
are the preferred nucleophile over water (in some cases with more than a 1000-fold preference). This 
allows the transphosphatidylation reaction to occur at very low concentrations of alcohol [24]. The use 
of ethanol or 1-butanol allows for a cumulative measurement of PLD activity, as the non-endogenous 
phosphatidylbutanol or phosphatidylethanol thus formed are relatively stable lipids [25]. 
The PLD activity is regulated by many factors including small GTPases, kinases or phosphoinositides. 
The first detected proteins activating mammalian PLD in vitro were ARF (ADP ribosylation factor) 
GTPases [26]. However, to this date the PLD binding site for ARF has not been unambiguously 
determined. It was assumed that the site might be located near the catalytic domain, because ARF 
activates N-terminally truncated PLD1 and PLD2 [16,27]. The ARF inhibitor Brefeldin A and the 
expression of dominant negative ARF1 or ARF6 blocked stimulation of PLD [28,29]. The Rho family 
of GTPases, including RhoA, Cdc42, Rac1, and Rac2, directly activates mammalian PLD. RhoA, 
Cdc42, and Rac1 selectively activate PLD1 [27]. However, a recent report suggests that Rac2 may 
activate PLD2 via a previously uncharacterized mechanism [30]. ARF and Rho family GTPases 
synergize to significantly increase PLD1 activity beyond an additive response. Pretreatment of 
Clostridium botulinum C3 toxin or Clostridium difficile toxins, all of which inactivate Rho proteins, 
blocks PLD activation [31]. Many studies have shown the regulation of PLD activity by protein kinase 
C (PKC). PKC activating factors including calcium ionophores and phorbol esters such as phorbol  
12-myristate-13-acetate (PMA), which is a stable analogue of diacylglycerol (DAG), are very potent 
activators of PLD. PKC inhibitors, such as staurosporine and calphostin C, block PLD activation [32,33]. 
The regulation of PLD by PKC appears most likely to involve direct interaction, phosphorylation and 
possibly other indirect mechanisms. In cells, the classic PKC isoforms α, β and γ stimulate PLD1 and 
PLD2 activity downstream of PLC activation. PKCα phosphorylates PLD1 and PLD2 at serine and 
threonine residues, but activation is not phosphorylation-dependent [34,35]. For the PLD1, the PKC 
binding domain was determined at the amino-terminus [36]. A meaningful overview about the complex 
regulation of PLD activation by PKC is summarized by McDermott and colleagues [37]. As mentioned 
above, mammalian PLDs have a PI4,5P2 binding domain. Therefore, PLD activity can be stimulated 
by PI4,5P2 and both PLD1 and 2 enzymatic activities are dependent upon PI4,5P2 [4,38]. Also, PIP3 
activates PLD with similar potency to PI4,5P2, but with reduced efficacy [4]. 
To study the PLD function, the most utilized class of molecule over the past 20 years has been 
primary alcohols (e.g., n-butanol). This is supplemented by overexpression of catalytically active or 
inactive forms of either PLD1 or PLD2 in vivo, or employed RNAi for the individual isoforms in  
an effort to discern discrete roles for PLD1 and PLD2. Recently, also deficient mice for studies have 
been available [39,40]. Nevertheless, to assess the therapeutic potential of the inhibition of PLD1 or 
PLD2, the genetic and biological data must be verified with a small molecule inhibitor. For decades, 
the quality of the inhibitors was not satisfactory. Whereas the first generation of PLD inhibitors such as 
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calphostin C [41] or curcumin [42] did not distinguish between PLD1 and 2 or also inhibit other signal 
pathways, the second generation with halopemide showed a clearly higher affinity, but also did not 
differ between isoforms [43]. Since 2009, the development of isoform-specific PLD inhibitor is driven. 
Today, highly potent PLD selective inhibitors are available that can be used in animal experiments. 
The review from Selvy et al. [11] described the development of VU0359595 as 1700-fold PLD1-selective 
inhibitor and VU0364739, a 75-fold PLD2-selective inhibitor. In addition to cellular effects, the 
inhibitors can be used to investigate the systematic PLD effects in whole organisms. 
3. GPCR Mediated PLD Signaling 
Signal-dependent activation of PLD enzymes has been demonstrated in numerous cell types for many 
GPCRs. Both PLD isoforms respond to the GPCR activation [44,45]. For example, this includes GPCRs 
such as μ-opioid [46], cannabinoid type 1 [47], formyl peptide [48] or D2 dopamine receptors [49]. It 
has been shown that both PTX-insensitive and PTX-sensitive G proteins are involved in stimulation of 
PLD by GPCRs [50,51]. Remarkably, the GPCR-induced PLD activation is mediated by distinct 
mechanisms. At first, Gα stimulates PLCβ hydrolysis of PI(4,5)P2, producing DAG and IP3. IP3 and 
DAG synergistically activate PKCα, which in turn bimodally activates PLD [11]. Dissociated Gβγ also 
activates PLCβ, to indirectly activate PLD in a PKC-dependent manner. On the other hand, Gβγ 
subunit of the heterotrimer can directly inhibit PLD activity via interactions through the PLD catalytic 
domain. Gβγ interaction disrupts both basal and ARF stimulated activity [52,53]. Second, the Gα12/13 
class of heterotrimers activates PLD in a small GTPase-dependent manner. Gα12 activates RhoA via 
Pyk2, a focal adhesion tyrosine kinase, which directly stimulates PLD1 activity. Third, Gα13 activates 
the γ subtype of PI3K to generate PIP3. Upon PIP3 binding, ARNO and Rho GEF trigger GDP for 
GTP exchange on Arf and RhoA, respectively. These activated small GTPases then directly activate 
PLD [54] (for the overview about GPCR mediated PLD signaling please see Figure 2). 
Interestingly, our own investigations revealed also a direct interaction between μ-opioid receptor 
and PLD2 [46]. Using a yeast two-hybrid technique, we identified the PX domain in the NH2 terminus 
of the PLD2 to be the important site for the interaction with the COOH terminus of the μ-opioid 
receptor. The results showed that only PLD2 and not PLD1 was associated with the μ-opioid receptor. 
A direct association of the PX domain in PLD2 was also shown for other receptors (e.g., epidermal 
growth factor, platelet-derived growth factor) [55,56]. Interestingly, our results demonstrated an increase 
of interaction between PLD2 and receptor after agonist treatment and that the PLD2 activation was 
ARF-dependent. However, for coimmunoprecipitation of μ-opioid receptor and ARF, the presence of 
PLD2 seemed to be required. Therefore, it is reasonable to assume that ARF binds directly to  
PLD2 rather than to μ-opioid receptor, but it cannot be excluded that a conformational change of the 
receptor in the μ-opioid receptor-PLD2 signaling complex is necessary to facilitate ARF binding to the 
receptor [46]. 
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Figure 2. G protein coupled receptor induced PLD activation and phosphatidic acid (PA) 
mediated signaling through Gαq and protein kinase C (A); Gα12 and RhoA (B); and Gα13 
and Arf (C). Modified from Selvy et al. [11]. 
 
PLD is a major source of PA generated by cell surface receptor-mediated signaling pathways. PA 
can be further metabolized to the GPCR agonist LPA (lysophosphatidic acid) by phospholipase A2 and 
to DAG by phosphatidate phosphohydrolase. However, GPCR-induced DAG production seems to 
mainly result from PIP2 breakdown by PLC [57]. PA directly binds to cellular proteins, such as Raf-1 
kinase, protein phosphatase 1, and mTOR, and can affect both cellular localization and activity of 
these proteins. For the Raf-1 kinase (which is activated by Ras), the recruitment to the plasma 
membrane requires a direct interaction with PA [58]. Raf-1 (c-Raf) kinase is a proto-oncogene and part 
of the ERK1/2 pathway as a MAP kinase kinase kinase (MAP3K) that functions downstream of the 
Ras subfamily of membrane associated GTPases [59]. For the protein phosphatase 1, PA is a potent 
and selective inhibitor [60]. mTOR (mechanistic target of rapamycin) regulates cell growth, cell 
proliferation, cell motility, cell survival, protein synthesis, and transcription and belongs to the 
phosphatidylinositol 3-kinase-related kinase protein family [61]. It is proposed that the responsiveness 
of mTOR/TOR to PA evolved as a means for sensing lipid precursors for membrane biosynthesis prior 
to doubling the mass of a cell and dividing [62]. PLD activity also contributes to key events in the 
oncogenic process including growth signaling, gatekeeper override, suppression of apoptosis, and 
metastasis [11]. However, a recent work did not confirm that a PLD induced PA formation is 
important for a mechanically induced increase of mTOR signaling [63]. In addition, PA is involved in 
a variety of signaling processes, such as activation of phosphoinositide (PI3K, PIP5K) and protein 
(Akt, ERK1/2) kinases, calcium mobilization, agonist-induced secretion and actin stress fibre 
formation, and extracellular signal-regulated kinase (ERK)-driven mitogenesis. Next, PA can activate 
PI4P5-kinase, the enzyme that produce PI(4,5)P2 [64]. In addition, it was shown that the  
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PLD2-phosphatidic acid-DAG pathway is involved in the opioid receptor-mediated activation of p38 
MAPK that is essential for μ-opioid receptor endocytosis [65]. However, the effects that are mediated 
by PA or via generation of LPA are multifaceted and not completely understood. 
4. PLD Influenced GPCR Functions 
PLD enzymes influenced GPCR functions about vesicle trafficking, endocytosis and recycling. The 
first descriptions showed that an overexpression of PLD enhanced internalization, whereas 
catalytically inactive mutants of PLD or the inhibition of PLD about primary alcohols inhibited 
endocytosis of receptors [66]. Depletion using PLD2 siRNA, but not PLD1, blocked agonist-induced 
endocytosis of the angiotensin II receptor [67]. Interestingly, a recent study showed that PLD1 as well 
as PLD2 inhibition via siRNA influenced formyl peptide receptor internalization [68]. However, both 
PLD isoforms modulate the receptor endocytosis by different mechanisms. Mammalian PLD enzymes 
differentially localize to cellular membranes to direct and indirect induce changes in membrane 
curvature and fusion that facilitate endocytosis/exocytosis and vesicular trafficking. Whereas the PLD2 
is located on the plasma membrane, the PLD1 primarily localizes to intracellular membranes. Upon 
cell stimulation, PLD1 translocates to plasma membrane and is activated [11]. 
PLD activation and subsequent PA accumulation facilitates vesicle budding and therefore receptor 
internalization and recycling. PA is a cone shaped lipid and induces changes in membrane curvature. It 
activates PI4P5K, which generates PI(4,5)P2 and induces translocation of coatomer proteins and 
proteins involved in vesicle budding, including dynamin (a GTPase involved in endocytosis and 
membrane scission) and AP180 (a clathrin assembly protein). Recently, PLD was also reported to 
directly interact with dynamin. This interaction occurred in a GTP-dependent manner, and it was 
suggested that the PX domain of PLD2 might serve as a GAP for dynamin [69]. Altogether, beside PA 
induced endocytosis, PLD itself influences vesicle scission by a direct interaction with dynamin. In 
most cases, the agonist-induced receptor endocytosis is clathrin-dependent and requires PLD activity. 
The activation of GPCR by agonist resulted in a phosphorylation of intracellular receptor domains by 
GPCR kinases or second messenger-regulated protein kinases, such as Ca2+/calmodulin-dependent 
protein kinase II. After phosphorylation of Ser/Thr residues on the C-terminus of the receptor,  
β-arrestins are frequently recruited to the plasma membrane, where they accelerate uncoupling of the 
receptor from the G protein and facilitate receptor endocytosis by serving as scaffolding proteins that 
bind to clathrin. One of the main regulators of the GPCR endocytosis is β-arrestins. Arrestins also 
interact with phosphoinositides such as PIP2 and PIP3; this interaction appears to play an essential role 
in mediating arrestin-promoted endocytosis of GPCRs [70]. The interaction of β-arrestins with 
endocytotic elements including clathrin and the adapter protein 2 (AP-2) are important for induction of 
clathrin-dependent GPCR endocytosis [71]. The recruitment of the AP-2 adapter complex is also 
facilitated by PA-mediated increase of PI(4,5)P2 level of the membrane [72–74]. Clathrin, dynamin 
and proteins of the AP-2 adapter complex contain domains that mediate their binding to  
PI(4,5)P2-containing membranes [75]. In addition, several groups reported that PLD2 was required for 
constitutive internalization of different GPCRs. The siRNA depletion of PLD2 function or the use of 
alcohol inhibited metabotropic glutamate receptors 1 and 5 endocytosis. Also, the constitutive 
internalization of the μ-opioid receptor was shown to be dependent on PLD2 [76]. 
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Figure 3. Regulation of G protein coupled receptor (GPCR) trafficking. Agonist binding to 
GPCRs leads to receptor activation, G protein coupling, and signal transduction including 
PLD activation. For example, whereas Gα12/13 class of heterotrimers or small G proteins 
such as ARF6 activates PLD, Gβγ subunit of the heterotrimer can directly inhibit PLD 
(step 1). G protein receptor kinases (GRKs) then phosphorylate the agonist-activated 
GPCR on intracellular domains, initiating arrestin recruitment. Arrestin binding to the 
receptor inhibits G protein coupling and terminates signaling, a process termed 
desensitization. PA-mediated increase of PI(4,5)P2 level facilitated recruitment of Clathrin, 
dynamin and proteins of the AP-2 adapter complex (step 2). Receptor/arrestin complexes 
are then targeted to clathrin-coated pits, where arrestin forms a multicomponent complex 
with clathrin, adapter protein-2 (AP-2), and phosphoinositides, resulting in receptor 
internalization. PLD directly interact with dynamin and it was suggested that PLD2 might 
serve as a GTPase activating protein (GAP) for dynamin (step 3). Internalized GPCRs are 
sorted (step 4) to degradation (step 5a) or recycling/resensitization (step 5b) compartments. 
ARF6 appears to be involved in the PLD mediated recycling. For details please see the 
paragraphs. Modified from Moore et al. [70]. 
 
Internalized receptors can be sorted to a degradative pathway and recycling pathway returning 
reactivated receptors to the plasma membrane [77]. Internalization, desensitization and receptor 
trafficking are the predominant mechanisms that control GPCR signaling. Thus, endocytosis serves 
multiple functions in regulation of GPCR signaling including signal termination, propagation, and 
receptor resensitization. Trafficking of internalized GPCRs from endosomes to lysosomes and consequent 
receptor degradation is also an important process that terminates receptor signalling [78]. Figure 3 
shows an overview about regulation of GPCR trafficking. The postendocytic fate of receptors is clearly 
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influenced by C-tail domains, binding partners and/or phosphorylation status [70]. In addition to 
endocytosis, there is evidence that PLD or PA influenced receptor recycling. In particular, ARF6 
appears to be involved in the PLD mediated recycling. It was reported that ARF6 is important for 
recycling of membrane proteins back to the plasma membrane [79]. The inhibition of ARF6 function 
about dominant negative ARF6 mutants resulted in a decrease of PLD2-mediated μ-opioid receptor 
recycling [80]. ARF6 and PLD2 seems to be associated with the endosomal membrane [81], but also 
the PLD1 is activated by ARF6 to facilitate exocytosis [82]. The generation of PA could lead to 
changes in membrane curvature that might facilitate vesicle fission or fusion [83]. Beside this, small 
Arf6 GTPase activating proteins ACAP1 and ACAP2 are regulated by PA [84]. In summary, numerous 
studies have demonstrated that agonist-induced GPCR endocytosis contributes to resensitization of 
signal transduction by receptor dephosphorylation and recycling to the plasma membrane [85–88]. The 
hypothesis is that the GPCR dephosphorylation and recovery from the desensitization requires 
endocytosis [70]. For the μ-opioid receptor, it has been demonstrated that the endocytotic efficacies of 
various opioid drugs are negatively correlated with their ability to cause receptor desensitization [86]. 
In support of this receptor recycling theory, opioid drugs with high endocytotic efficacies induced less 
opioid tolerance than non-internalizing agonists in rats [89]. These findings support the hypothesis that 
μ-opioid receptor endocytosis counteracts the development of opioid receptor desensitization and 
tolerance [86]. However, more recent studies have found that endocytosis seems to be not required for 
either recovery from desensitization or dephosphorylation of μ-opioid receptor [90–92]. It remains to 
note that the necessity for endocytosis and recycling to dephosphorylate some GPCRs presumably 
depends on the affinity of arrestins for the agonist occupied receptor. In fact, the affinity of the  
β-arrestin 2 to μ-opioid receptor is relatively weak, whereas GPCRs with strong β-arrestin 2 interaction 
such as angiotensin II receptors still need endocytosis to dissolve β-arr2-receptor interaction and 
uncover the phosphorylation sites for phosphatases [70]. 
5. Pathophysiological Implications of PLD 
The systematic investigation of PLD as a therapeutic target has just started in the past few years. 
Recent reports suggest the high therapeutic potential of PLD inhibition in Alzheimer’s disease [93–95], 
stroke [96] and cancer treatment [97,98]. For Alzheimer’s disease, an increased PLD activity was 
found in post-mortem brains of Alzheimer patients [99] and in a mouse model of Alzheimer’s disease. 
Interestingly, PLD2 ablation via gene targeting rescues memory deficits and confers neuronal 
protection in a mouse model of Alzheimer’s disease despite a significant amyloid β (Aβ) load [93]. In 
addition, several publications showed an involvement of PLD in Aβ species signaling [95,100]. 
Furthermore, our in vitro results provide evidence for PLD-dependent Aβ1-42 internalization as well as 
ERK1/2 phosphorylation and the involvement of PI-3-kinases in Aβ1-42-induced formyl peptide receptor 
like-1 (FPRL1) activation [95]. The involvement of the GPCR FPRL1 in Aβ1-42-induced cell 
activation was supported by further studies [101–103]. Altogether, these studies clearly show that PLD 
or PLD-mediated PA production could be involved in the development of the Alzheimer’s disease. 
Therefore, the discovery of highly potent and selective PLD inhibitor or PLD knockout mice will 
facilitate target validation in animal models of disease. One could speculate if PLD inhibition could 
also be relevant for mechanically driven disease like osteoarthritis. 
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6. Conclusions and Future Perspectives 
During the last decades, a high research effort was made to understand the functions and role of  
the PLD in the context of membrane function. It has been shown that the PLD contributes to a variety 
of mechanisms to modulate GPCR signalling or function. The numerous protein–protein and  
protein–lipid interactions of the PLD emphasize the key position of the enzyme in the temporal and 
spatial dynamic organization of phospholipid signalling and GPCR function. However, several 
questions remain unanswered and require further investigations. Future investigations might focus on 
the possible changes of the PLD-receptor interaction in the context of various diseases and to search 
for further interaction with other small G-proteins or signal pathways. Thus, it seems reasonable to 
suggest that in the next years some expected exciting and encouraging results about PLD as a 
therapeutic target could be expected. In addition, the possible role of PLD mediated endocytosis 
counteracting the development of opioid tolerance in the context of pain or addiction could be an 
interesting intervention points for the therapy of opioid addiction and tolerance. The complex function 
of the PLD enzyme clearly shows how biological systems control the activity of membrane receptors 
to regulate a diversity of cellular processes. In conclusion, the future studies dealing with the 
mentioned topics will lead to a more complete understanding of PLD enzymes and GPCR function and 
regulation. 
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